Introduction
The p53 tumor suppressor gene plays a key role in human carcinogenesis through regulating its target genes involved in cell cycle control and apoptosis in response to cellular [ ] damage 1 . Inactivation of the p53 gene appears to be the most common genetic alteration in human cancers and contributes to the development of over 50% of all human [ ] cancers 2 . Recently, two of the p53 structural homo-( ) logues, p51 also designated as p40, p63 and p73L and [ ] p73, were cloned 3 -8 . Because both p51 and p73 share critical functions with p53, including the induction of growth arrest and apoptosis, it is important to elucidate the functions of the newly identified p53 family of genes in more detail in association with human carcinogenesis.
To date, mutations of the p51 gene were detected only in [ ] 3 of 101 primary tumors and cancer cell lines 3 . Thus, it has been considered that p51 mutation occurs rarely in [ ] human cancers, as in the case of the p73 gene 9,10 . However, it is still possible that the p51 gene is frequently mutated in certain types of human cancers, particularly in cancer cells without p53 mutations. It is also possible that p51 is inactivated by mechanisms other than genetic alterations, including transcriptional silencing and expression of a dominant-negative form of the protein. To perform a detailed molecular analysis on the status of the p51 gene in human cancer cells, it is indispensable to determine the genomic structure of the p51 gene. For this reason, we first determined the genomic structure and designed intron-based primers for the mutation analysis of the p51 gene.
Yang et al. reported that there are at least 6 major types ( ) of p51 mRNA transcripts. Three of them TA isotypes encode proteins with the transactivation domain, DNA binding domain, and oligomerization domain, whereas the other ( ) three DN isotypes encode proteins without the acidic [ ] N-terminal domain, which is required for transactivation 7 . The DN isotypes of p51 proteins were predominantly expressed in a variety of epithelial cells and could act as dominant-negative agents toward the TA isotypes of p51 protein as well as p53 protein. Thus, it is also important to elucidate which types of p51 protein are predominantly expressed in human cancer cells.
In this study, we performed structural analysis of the p51 gene and its transcripts in human lung cancer cells for the following reasons. First, the p51 gene has been mapped to [ ] chromosome 3q28 3 , and comparative genomic hybridiza-( ) tion CGH analysis indicated that this chromosomal region [ ] is frequently amplified in human lung cancers 11 -16 . Second, a subset of lung cancers does not have mutated p53 genes, and responsible genes for the development of those cancers have not been identified yet. Third, a p51 mutation was previously detected in an undifferentiated [ ] squamous cell carcinoma of the lung 3 . We determined the exon-intron structure of the p51 gene and intron sequences flanking all 15 coding exons and designed 15 sets of intron-based primers for the mutation analysis of the p51 gene. Then 44 cases of lung cancer cell lines and 45 cases of primary lung cancers were screened for mutations in the entire coding region as well as intronic splicing donor and acceptor sites of the p51 gene by polymerase chain reac-( ) tion-single strand conformation polymorphism PCR-SSCP analysis. We also performed reverse transcriptase-poly-( ) merase chain reaction RT-PCR analysis to identify the isotypes of p51 transcripts that are predominantly expressed in lung cancer cells.
Materials and Methods

Samples
Forty-four lung cancer cell lines, including 33 non -small ( ) cell lung carcinomas NSCLCs and 11 small cell lung ( ) carcinomas SCLCs were used in this study . NSCLC cell  lines were A427, A549, PC3, PC7, PC9, PC14, LCMS, H23,  H441, H322 
Determination of the Exon-Intron Organization
Genomic DNA fragments covering the p51 gene locus were obtained by the following procedure. First, several sets of PCR primers based on the cDNA sequence were designed to construct a contig of genomic DNA fragments covering the p51 locus. One hundred nanograms of genomic DNA from human colon cancer cell lines, LoVo and HCT116, were used for PCR. PCR products were electrophoresed on 0.8% agarose gel, and their sizes were compared with those of the corresponding cDNA fragments. Amplified DNA fragments containing introns were sequenced to design intron primers. Next, human bacterial ( ) ( artificial chromosome BAC DNA Pools Release IV Re-) search Genetics was screened by PCR with 3 sets of intron-based primers, which amplified exons 2, 6, and 15 of ( ) the p51 gene at 158C, and exposed to Kodak XAR films for 24 to 48 hours at y808C. PCR products showing different mobilities were purified and directly sequenced in both directions.
Sequence Analysis PCR fragments were purified by using QIA quick-spin ( ) PCR purification kit QIAGEN and directly sequenced by using Thermo Sequence dye terminator cycle sequencing ( ) pre-mix kits Amersham Pharmacia Biotech and ABI 373S ( ) DNA Sequence System Perkin-Elmer . DNA from BAC clone was sequenced by using the fmol DNA Sequencing ( ) System according to the supplier's protocol Promega .
Southern and Northern Blot Analyses
Southern and Northern blot analyses were carried out [ ] under the stringent condition described previously 20 . Genomic DNA was digested with EcoRI and electrophoresed for Southern blot analysis. The cDNA fragment correspond-( ing to nucleotide 170 -781 of p51A cDNA Accession No. ) AB016072 in Genbank was used for hybridizations as a probe.
Reverse Transcriptase-Polymerase Chain Reaction Analysis Randomly primed cDNAs were reverse-transcribed from 0.5 mg mRNAs by using SuperScript II Rnase H-Reverse ( ) Transcriptase Gibco BRL in a 20-mL mixture according to the supplier's protocol. One microliter of the cDNA conversion mixture was amplified by PCR in a 10-mL reaction mixture. PCR conditions were as follows: 30 seconds at 958C, 30 seconds at 558C or 608C, and 90 seconds at 728C for 35 cycles, followed by 10 minutes at 728C. The following primers were used: TA, 5
X -ATGTCCCAGAGCACACAG-3
and 5 X -CGTCAGATTGTTTTG-GAGTTT-3 X . PCR products were electrophoresed on 2.0% agarose gel and stained with ethidium-bromide.
Results
Genomic Structure of the p51 Locus It was previously shown that the p51 gene consisted of [ ] 16 exons and 15 introns 7 . Exon 1 is a noncoding exon, whereas all others are coding exons. Genomic structure of exons 2 to 15 was determined by the following methods. A remarkable conservation of exon-intron organizations between two of the p53 family genes, p53 and p73, permitted us to estimate intron positions of the p51 gene. We therefore designed PCR primers that would specifically anneal to regions in possible contiguous exons of the p51 gene. Genomic DNA fragments that contained introns 2, 5, 6, 7, 8, 9, and 15 were successfully amplified and sequenced to design sets of intron-based primers that specifically amplified exons 2, 6, 7, 8, 9, and 15. Then, these sets of primers were used to screen a BAC library. A BAC clone, 224P11, covering exons 2 to 15 of the p51 locus, was obtained and used to determine the sequences of the remaining flanking introns.
It was previously shown by the structural analysis of p51 cDNA that there are two different start codons and two [ ] different stop codons in the p51 gene 7,8 . The ATG start codons were located in exons 2 and 3 X , and the stop codons were located in exons 14 and 15. The structure determined in this study was consistent with the one determined by [ ] Yang et al. 7 . The putative transactivation domain, DNA binding domain, and oligomerization domain were encoded in exons 2 to 3, exons 4 to 8, and exons 9 to 10, respectively. Two major splicing forms of the p51 gene, p51A and ( ) p51B also designated as TAp63g and TAp63a , were derived from exons 2 to 10 and 15, and exons 2 to 14, respectively. The sequences of whole exons in the BAC clone were identical to those of the p51 cDNAs, and all [ ] exon-intron junctions followed the GT -AG rule 21 . The boundary sequences of each exon-intron are shown in Figure 1 . Comparison of the genomic organization between p51 and the other two p53 family genes revealed that the exon boundary positions and exon sizes of the p51 gene were highly homologous to those of the p53 and p73 genes. In contrast, the homologies in the size and sequence of introns were not so high among these three genes [ ] 22,23 .
Genetic Alterations of the p51 Gene in Lung Cancers
PCR amplification of genomic DNA from cell lines and primary tumors was performed by using the intron-based ( ) primers for each of the 15 coding exons Table 1 . The size of each PCR fragment was less than 500 bp and was [ ] suitable for SSCP analysis in the low pH buffer system 16 . Forty-four lung cancer cell lines and 45 primary lung cancers were analyzed for p51 mutations and polymorphisms. A mutation was detected in a squamous cell carcinoma cell ( ) line, EBC1 Figure 2 . Sequence analysis of DNA from Table 3 .
Four different types of genetic polymorphisms were detected. A silent polymorphism was found at codon 248 in exon 6, and three others were located in introns 5 and 8 ( ) Table 2 . Thus, there was no genetic polymorphism by which p51 protein with different amino acid sequence could be expressed.
We further searched for genetic alterations in the p51 locus by Southern blot analysis. There were no amplification, homozygous deletion, and rearrangement of the p51 ( ) gene in 42 lung cancer cell lines data not shown .
Expression of the p51 Transcripts in Lung Cancers
We first examined the expression of the p51 gene in lung cancer cell lines by Northern blot analysis. p51 transcripts ( ) were detected in 23 of 43 cell lines. In each cell line, major transcripts of either 4.4 kb or 3.8 kb in size were detected. The levels of p51 expression were variable among cell lines and relatively high in H322, Ma3, Ma10, Ma24, H596, PC10, ( ) and LC1-Sq Figure 3A , Table 3 . Cell lines with high levels of p51 expression were derived either from adenocarcinoma or squamous cell carcinoma and were not from large cell carcinoma or small cell carcinoma. However, apparently no correlation was observed between the level of expression and the histology of cell lines. The p53 gene is not mutated ( ) in 7 A427, A549, Ma12, Ma17, Lu99A, Lu24, and H209 of ( ) the 43 cell lines examined Table 3 . Among them, a low level of p51 expression was detected in Ma12 only, and p51 transcripts were not detected in the remaining 6 cell lines. Thus, it is possible that the p51 gene is not expressed in most of lung cancer cells with wild type p53 expression.
Up to the present, six of alternatively spliced p51 transcripts have been identified, and they encode proteins with ( ) two different N termini TA and DN and three different C ( )[] termini a , b, and g 7 . To obtain more detail information on p51 expression in lung cancers, we performed RT-PCR analysis with 4 sets of primers that specifically amplified the ( ) TA, DN, a and b, and g isotypes Figure 3B . Expression patterns of these isotypes in each cell line are summarized in Table 3 . The result of RT-PCR analysis was almost consistent with and similar to that of Northern blot analysis. Either one or more p51 isotypes were detected in 34 of 44 cell lines. p51 transcripts were also detected by RT-PCR analysis in all three of normal lung tissues. There was no correlation between the isotypes expressed and histology of cell lines. Interestingly, all of 7 cell lines expressing high levels of p51 expressed the DN isotype that inactivates the [ ] function of the TA isotype transdominantly 7 . The a and b isotypes were not detected in normal lung tissues, although those two isotypes were detected in most lung cancer cell lines.
We found a novel p51 variant that was amplified by using ( a set of primers specific for the a and b isotypes Figure ) 3B, Table 3 . This variant was derived from an alternative splicing from exon 11 to exon 14, thus, lacked exons 12 and ( ) 13, and was designated the d isotype Figure 4A . The d isotype was expressed in 18 of 44 lung cancer cell lines and 2 of 3 normal lung tissues. To examine the tissue distribution of the d isotype, we performed PCR analysis with cDNAs from various normal human tissues. Expression of the d isotype was detected in uterus, thymus, placenta, mammary gland, and fetal lung, and not detected in kidney, stomach, small intestine, spleen, bone marrow, brain, spinal cord, testis, skeletal muscle, adrenal grand, salivary grand, ( ) pituitary gland, fetal liver, and fetal kidney Figure 4b .
Among the 7 cell lines without p53 mutations, RT-PCR products were detected in 3 cell lines, A549, Ma12, and Lu24. In all the 3 cell lines, the TA isotype but not the DN isotype was detected, suggesting that the function of wild-type p53 protein is not suppressed by expression of dominant-negative p51 protein in these cell lines. Absence of transcription would be a more common phenomenon in lung cancer cells with the wild-type p53 gene, as suggested by Northern blot analysis. In contrast, expression of the DN isotype was detected in 11 cell lines, and all of them had mutated p53 gene. Thus, in cell lines with p53 mutations, the function of the p51 gene might be also inactivated in part by expression of dominant-negative DN isotype p51 protein.
Although major transcripts of either 4.4 kb or 3.8 kb were detected by Northern blot analysis, the association between the sizes and the isotypes of mRNA transcripts is presently unknown. 
Discussion
Here we determined the genomic structure of the p51 gene and, based on this data, we designed 15 sets of primers for mutation analysis of all the coding sequences of the p51 gene. Previous mutation analysis of the p51 gene showed that the p51 gene was mutated in a lung squamous cell ( ) carcinoma, a head and neck cancer cell line Ho-1-u-1 , and ( )[ ] a cervical cancer cell line SKG-III 3 . We therefore performed mutation analysis of the p51 gene in human lung ( ) cancer. A mutation was detected in only one of 89 1.1% lung cancers. Thus, mutation of the p51 gene rarely occurs in lung cancer cells. Mutations detected in the previous ( study were located in exon 4 a lung squamous cell carci-) ( ) noma and Ho-1-u-1 or exon 5 SKG-III . A mutation we found in this study was also located in exon 5, which encodes the putative DNA binding domain. These results suggest that mutations of the p51 gene cluster in the DNA binding domain, as in the case of mutations in the p53 gene [ ] 24 . The result may also suggest that p51 mutations occur in a small subset of squamous cell carcinoma and not in other histological types of lung cancer. Although the present result indicated that the p51 gene is infrequently mutated in lung cancers, intron-based primers designed in this study will be useful for the molecular analysis of the p51 gene in a variety of human cancers.
Amplification of genes in the 3q28 region has been suggested to occur in lung cancer cells by the CGH analysis [ ] 11 -16 , however, amplification of the p51 gene at 3q28 was not detected by Southern blot analysis. Thus, the p51 gene would not be a target of gene amplification at 3q28 in lung cancer cells.
Northern blot analysis as well as RT-PCR analysis revealed that the p51 gene is expressed in a large subset of lung cancer cells and the levels of p51 expression vary considerably among lung cancer cells. Thus, it would be of great interest to clarify the association of p51 expression with biological properties of lung cancer cells. It is possible that expression of the p51 gene is silenced in a subset of lung cancer cells by several mechanisms, including DNA [ ] methylation in the promoter region 25,26 . If so, transcriptional silencing would be one of the mechanisms for p51 inactivation. For this reason, molecular analysis of the promoter region is now in progress in our laboratories.
It is noted that the DN isotype of mRNA transcripts was expressed in cell lines with high levels of p51 expression. Because the DN isotype encodes a protein that transdominantly suppresses the transactivation function of p51A ( ) TAp63g as well as p53, it was suggested that the p51 gene, and possibly the p53 gene, is functionally inactivated in lung cancer cell lines in part by expression of the dominant-negative DNp51 protein. However, because all the cell lines that express the DN isotype of mRNA transcripts carry mutated p53 genes, the interaction between the DN isotype of p51 protein and mutated p53 protein remains unclear. Further studies are required to resolve this question.
The a and b isotypes were not detected in normal lung tissues, whereas they were detected in most lung cancer cell lines. However, the biological significance of this finding is unclear at present because the functional differences among a , b, g, and d isotypes are unknown.
Presence of a novel isotype of p51 mRNA transcripts also indicated that the complexed functions of the p51 gene can be regulated partly by alternative splicing of the p51 transcripts. Recently, two novel p73 splicing variants, p73g and p73d, were identified in addition to p73a and p73b. It has been suggested that p73 provides a complex regulatory mechanism to the control of cell growth, because of different expression patterns for the four splicing variants in normal and neoplastic cells, and of homodimeric and het-[ ] rodimeric interactions of various p73 isotypes and p53 27 . Understanding the interaction between various isotypes of p51 protein, as well as p53 and p73, would be of great importance in clarifying the mechanisms for regulation of cell growth and apoptosis in cancer cells. 
